Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase - Test2 - elhamkhani - TriplyDB

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

http://www.wikidata.org/entity/Q33688165

about

Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI Respiratory and sleep disorders in mucopolysaccharidosis Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA Management of Life-Threatening Tracheal Stenosis and Tracheomalacia in Patients with Mucopolysaccharidoses Mucopolysaccharidosis VI.Long-term cognitive follow-up in children treated for Maroteaux-Lamy syndrome.Ethical and economic considerations of rare diseases in ethnic minorities: the case of mucopolysaccharidosis VI in Colombia.Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.Reduced Arylsulfatase B activity in leukocytes from cystic fibrosis patients Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series Haploidentical stem cell transplantation in two children with mucopolysaccharidosis VI: clinical and biochemical outcome.Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.Diagnosis of the mucopolysaccharidoses.Therapy for the mucopolysaccharidoses.Current and potential therapeutic strategies for mucopolysaccharidoses.Clinical Evolution After Enzyme Replacement Therapy in Twins with the Severe Form of Maroteaux-Lamy Syndrome Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy.Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series.Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation.

P2860

Q24186047-7274377D-1444-4CAD-991C-79030AEF171E Q24198820-C3B1888A-1164-4D35-BBF3-B981FF116465 Q30457547-BD8DF7AD-8D0C-4551-9E69-9C46A7A6068B Q30537233-4C9E33FF-3C31-4B82-BFF5-C2F645986422 Q33627548-D72E07E0-168B-44CA-9B66-DD6B5D1762DF Q33863356-F408FA4F-1C2D-4655-BE65-2AF41AEC8390 Q36582221-353883AC-0133-42CC-9420-04194971D9C9 Q36637927-76B14FA8-3E55-4BCB-9BA2-FB5747D1AA39 Q36662791-E49CA66F-4A79-4645-8F23-216079FA9F26 Q36797802-B6CF24F9-389B-477C-88DE-D01BE7F99F63 Q36802440-A1FA885F-86F3-46B8-85E4-F9853D8744E5 Q36806851-49EACB8B-95C0-4F96-A16A-CE1E905191E0 Q37154973-F749620A-F58B-4FD0-B5AE-198F38B6BCB9 Q37341874-7774C614-D775-4967-B2EC-608B18B950B4 Q37972590-90D3425C-709A-4F15-8CC0-4D7E611812AF Q37972592-95E01D9F-385A-478C-AFCC-A9A8478EB664 Q38194635-768738CC-BE05-4739-823A-F063E5F408E2 Q42368422-66C68120-3C0E-4219-B3E7-FC14F8D3FAA0 Q46739999-D8379500-C92D-4506-8B5C-2902EFF07C6F Q46869287-0B2FE0A1-45AB-4EB9-86B9-B20CBFFC7F9E Q47990521-68103A2F-A19E-4DCF-BA73-922E848F5965 Q52902721-095CFBF0-B6A4-4340-87AB-90269240A835 Q53380756-C1047C7B-7CAF-49F8-8FD1-4DE6FD5ED00C

P2860

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

http://www.wikidata.org/entity/Q33688165

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Enzyme replacement therapy for ...... cetylgalactosamine 4-sulfatase

@ast

Enzyme replacement therapy for ...... cetylgalactosamine 4-sulfatase

@en

type

label

Enzyme replacement therapy for ...... cetylgalactosamine 4-sulfatase

@ast

Enzyme replacement therapy for ...... cetylgalactosamine 4-sulfatase

@en

prefLabel

Enzyme replacement therapy for ...... cetylgalactosamine 4-sulfatase

@ast

Enzyme replacement therapy for ...... cetylgalactosamine 4-sulfatase

@en

P1433

Q33688165-CAAEE985-3DD5-444C-ABB0-092E41C211AC

P1476

Q33688165-2A99D971-4DDE-4086-8097-ECA469D3C40A

P2093

Q33688165-1CD83273-63D4-471B-945B-E245D86B7106

Q33688165-311EC788-E8B3-4C94-9AB5-AEB1D0676CF4

Q33688165-5241E489-8AC3-4357-9721-791C2FF65354

Q33688165-54DFEE88-DE97-43CA-9D00-204A285CE84C

Q33688165-5BD69512-BEAC-4378-8774-CC5C372A8C2C

Q33688165-6B0FDA6E-E4DF-44B2-A676-7F34ED04C32F

Q33688165-79B291CB-0BC4-4320-8AAA-D1CBDA3FD34A

Q33688165-7C622908-BF7B-4E56-AAF3-F6071744A4FB

Q33688165-938F3564-ED23-4607-A105-C79B707712C1

Q33688165-9B1B79F0-E557-4CB0-BDDA-9BB02021CEEE

P2860

Q33688165-071D9E92-F1AE-4846-AE91-B7F9698E84F9

Q33688165-11FB6F60-391E-4DA2-8591-CEF2AEBFD18F

Q33688165-2B729B26-5223-4A9B-BC7A-63B5C9DEE471

Q33688165-2CFAA291-FE0A-4363-A65A-04C94F32239C

Q33688165-440BBE80-26A9-40D1-8DED-645EEA124ED9

Q33688165-7A6948B2-6240-4C31-9AD8-49E2F62CB04D

Q33688165-85FD2E1F-3D7D-48C7-A068-5E9876E5D07D

Q33688165-883E8B8F-63D3-4BA7-9581-81CFC894A1FD

Q33688165-A345C1B6-68B8-4374-ACBE-1F6E0884070C

Q33688165-B8E15D65-513B-427F-A039-247789F3792A

P2888

Q33688165-31F5BAEB-1F30-4B5E-BE1C-FA73F1A4C416

P304

Q33688165-AB72665A-91CB-4A1D-9583-DADA04997C88

P31

Q33688165-67146687-E32B-4707-8341-D1790584CE15

P356

Q33688165-5C653D40-4D7D-47AC-B7AE-B9618919ED92

P433

Q33688165-14DB5337-83EE-4182-A802-BB397D504940

P478

Q33688165-2E61DE7B-1B69-4734-8682-0FECDF067EDE

P50

Q33688165-54917D20-6139-4466-BD3A-58598646CB76

Q33688165-64454925-14B7-4CB0-A291-09A9D641E9C3

P577

Q33688165-5039ACFC-283E-4C64-B094-2405EB08C86D

P5875

Q33688165-F02DD539-E3C3-430F-B2AB-46E7EE56F454

P6179

Q33688165-AA56CC74-4F3D-4647-88E7-8F08B484310D

P698

Q33688165-ACC2A5E6-C3CD-49B8-80CF-91ED8C23E561

P921

Q33688165-9F8A4E32-FB01-4964-9455-C015331D94BB

P932

Q33688165-C782420C-9E58-41CF-AB50-ADA53592C4D7

P356

S10545-009-9007-8

P1433

Journal of Inherited Metabolic Disease

P1476

Enzyme replacement therapy for ...... cetylgalactosamine 4-sulfatase

@en

P2093

Barbara Plecko

http://www.w3.org/2001/XMLSchema#string

Celeste Decker

http://www.w3.org/2001/XMLSchema#string

Chester B Whitley

http://www.w3.org/2001/XMLSchema#string

David Ketteridge

http://www.w3.org/2001/XMLSchema#string

Elisa Leão Teles

http://www.w3.org/2001/XMLSchema#string

Ida Vanessa D Schwartz

http://www.w3.org/2001/XMLSchema#string

J Edmond Wraith

http://www.w3.org/2001/XMLSchema#string

John J Hopwood

http://www.w3.org/2001/XMLSchema#string

Karen Hardy

http://www.w3.org/2001/XMLSchema#string

Laila Arash

http://www.w3.org/2001/XMLSchema#string

P2860

Interpretative strategies for lung function tests

Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies.

Standardization of Spirometry, 1994 Update. American Thoracic Society

Otorhinolaryngological manifestations of the mucopolysaccharidoses.

Lung function in white children aged 4 to 19 years: I--Spirometry

Management guidelines for mucopolysaccharidosis VI.

Prediction of maximum voluntary ventilation (MVV) in African-American adolescent girls.

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

The lungs and airways in achondroplasia. Do little people have little lungs?

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

P2888

s10545-009-9007-8

P304

51-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10545-009-9007-8

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth I. Berger

Robert D. Steiner

P577

2010-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41415028

http://www.w3.org/2001/XMLSchema#string

P6179

1042928055

http://www.w3.org/2001/XMLSchema#string

P698

20140523

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

2828556

http://www.w3.org/2001/XMLSchema#string